ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1958

Contribution of MOCS on Xanthinuria Type III and Its Clinical Significance for Screening

Sung Kweon Cho1 and Blanka Stiburkova 2, 1NCI, Frederick, MD, 2Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: xanthinuria

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Xanthinuria is a rare inherited disorder of purine metabolism (1 in 69,000). In the first step, determination of serum and urinary uric acid and purine profile is

important to establish the diagnosis of xanthinuria. Second, xanthinuria is typed using urinary metabolomics. Finally, the results are confirmed by molecular genetics.1 Here, we aimed to identify genetic variants in the xanthiuria patient using whole-exome sequencing (WES) and evaluated its functional variants.

To distinguish the types of HX, allopurinol loading test and invasive intestinal or liver biopsy have been traditionally used because XDH/XO activity in humans is expressed only in the small intestine and liver.

Methods: 43-year-old female (Roma ethnic group) visited the outpatient clinic. She was diagnosed as xanthinuria based on biochemical lab data (serum uric acid 70 µmol/L, FE-UA: 8.6%, urinary hypoxanthine 52.6 mmol/molCr and urinary xanthine 186.3 mmol/molCr). Conventional genotyping of XDH/XO, AOX and MOCOS does not find the causal variant. WES and corresponding downstream analyses were performed for the discovery of coding causal variants further evaluation and we compared the result to WES of 31 hypouricemia patients in Korean.

Results: Considering its prevalence and recessive inheritance, 34 candidate variants were identified after filtering out allele frequency threshold in Non-Finish European. Based on known gene list, homozygote mutation of p.Leu19Phe in MOCS2 (MIM : 603708) was identified for the causal variants. Functional prediction tool indicated that the variants was found to be damaging (0.58, Polyphen2), disease causing (0.686, Mutation Taster) and CADD score of 16.62. After investigating 31 hypouricemic Korean patients for the replication, we found a truncating p.Arg132* variant of MOCS1 (MIM: 603707) in patients who have homozygous variants of SLC22A12.

Conclusion: This shows the value of MOCS genes for xanthinuria for the first time. Early genetic identification  may prevent acute kidney injury or nephrolithiasis.


Disclosure: S. Cho, None; B. Stiburkova, None.

To cite this abstract in AMA style:

Cho S, Stiburkova B. Contribution of MOCS on Xanthinuria Type III and Its Clinical Significance for Screening [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/contribution-of-mocs-on-xanthinuria-type-iii-and-its-clinical-significance-for-screening/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-mocs-on-xanthinuria-type-iii-and-its-clinical-significance-for-screening/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology